Exegenesis Bio designed EMC181 to improve the delivery of genetic medicines to muscle tissue while limiting exposure to the liver.
The approach is intended to support drug discovery in neurology, where diseases often arise from complex interactions involving genetic, developmental, neural network, immune and environmental factors.
The collaboration combines Weave Bio’s artificial intelligence tools with Takeda’s regulatory expertise to simplify and speed up activities involved in preparing submissions and responding to questions from health authorities.
The agreement establishes a framework for broader cooperation between the two institutions as they respond to changing healthcare needs in Qatar.
The platform has grown to serve about 70,000 members across more than 400 companies and connects users with more than 1,200 pharmacies and healthcare providers in the two countries.
The hospital will coordinate the collection, while Sidra Medicine will process and store the samples at its specialized Good Manufacturing Practice (GMP) facility, which houses Qatar’s only cord blood bank.
Under the partnership, M42 will support Botswana’s efforts to transform its healthcare system through digital health, genomics, precision medicine and workforce development.
Through its collaboration with Thmanyah, Bupa Arabia aims to make discussions about health and wellbeing more relevant to people’s everyday lives.
The agreement builds on Peking University’s longstanding involvement in global health research and public health capacity development.
As part of the agreement, Charles River will use technologies such as next-generation sequencing (NGS) to support chemistry, manufacturing and controls (CMC) activities associated with the vaccine programme.